Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

To reduce doxorubicin, bleomycin, vinblastine and dacarbazine toxicity, the Cancer and Leukemia Group B conducted a phase 2 trial of doxorubicin, vinblastine, and gemcitabine for newly diagnosed, nonbulky stages I and II Hodgkin lymphoma. Ninety-nine assessable patients received 6 cycles of doxorubi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Straus, David J., Johnson, Jeffrey L., LaCasce, Ann S., Bartlett, Nancy L., Kostakoglu, Lale, Hsi, Eric D., Schöder, Heiko, Hall, Nathan C., Jung, Sin-Ho, Canellos, George P., Schwartz, Lawrence H., Takvorian, Ronald W., Juweid, Malik E., Cheson, Bruce D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3109706/
https://ncbi.nlm.nih.gov/pubmed/21355087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-10-314260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados